Beta
Alirocumab
medicationPCSK9 inhibitor (brand name: Praluent) - injectable biologic for cholesterol management. Similar effectiveness to Repatha.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Alirocumab to your stack to report effects
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of the Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody Alirocumab in Healthy Chinese Subjects
Y. Li, et al.
A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of the PCSK9 Inhibitor Alirocumab According to Injection Site in Healthy Subjects
R. Dent, et al.
Population Pharmacokinetic Analysis of Alirocumab, a Fully Human Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody
R. P. Allaire, et al.
No reports yet
Be the first to report this effect and help the community.
Add Alirocumab to your stack to report effects
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of the Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody Alirocumab in Healthy Chinese Subjects
Y. Li, et al.
A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of the PCSK9 Inhibitor Alirocumab According to Injection Site in Healthy Subjects
R. Dent, et al.
Population Pharmacokinetic Analysis of Alirocumab, a Fully Human Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody
R. P. Allaire, et al.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Research (3 studies)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of the Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody Alirocumab in Healthy Chinese Subjects
Y. Li, et al.
Population Pharmacokinetic Analysis of Alirocumab, a Fully Human Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody
R. P. Allaire, et al.
A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of the PCSK9 Inhibitor Alirocumab According to Injection Site in Healthy Subjects
R. Dent, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!